Effects of Intravenous Administration of Vancomycin on Peritonitis in a Patient on Peritoneal Dialysis
In settings where intraperitoneal vancomycin is unavailable or off-label (e.g., Japan), intravenous vancomycin can be a viable treatment option for peritoneal dialysis-associated peritonitis. Due to limited pharmacokinetic data regarding intravenous dosing, pragmatic strategies involving more frequent therapeutic drug monitoring-measuring both serum levels for systemic safety and dialysate levels for intraperitoneal antimicrobial exposure-can help ensure therapeutic efficacy while maintaining patient safety.
Authors
- Nobuaki Kikuchi (ORCID: https://orcid.org/0000-0003-0197-466X)
- Hiromi Koshizuka (ORCID: https://orcid.org/0000-0002-5826-6755)
- Kenji Momo (ORCID: https://orcid.org/0000-0001-9856-0097)
- Yuka Kashiwabara
- Natsuri Yonezawa
- Tomoaki Miyazaki (ORCID: https://orcid.org/0000-0001-6027-9048)
- Tatsuki Iha
- Akira Ito (ORCID: https://orcid.org/0000-0002-5070-9187)
- Ayako Watanabe (ORCID: https://orcid.org/0000-0003-3844-1891)
- Akio Koizumi
- Akiko Takeshima
- Kunio Matsumoto (ORCID: https://orcid.org/0000-0002-6532-4482)
Institutions
- SHOWA Medical University Hospital (JP)
Publication Details
- Journal
- Clinical Case Reports
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/ccr3.71494
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 0.00